|
New Release of Genedata Expressionist For Innovative Characterization and Automated Quality Monitoring of Next-Generation Biotherapeutics
Wednesday, October 26, 2022
Latest enterprise software release expands functionalities for comprehensive characterization and quality monitoring of biopharmaceuticals
BASEL, Switzerland, Oct. 18, 2022 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Expressionist® 16.5, the latest version of its platform for streamlining and automating mass spectrometry data workflows, from early discovery to late-stage development. Genedata Expressionist 16.5 takes characterization and quality monitoring of biotherapeutics and oligonucleotides to the next level by enabling leading biopharma companies to fully leverage the potential of mass spectrometry data in their R&D workflows, irrespective of the instrument or technology applied.
Genedata Expressionist 16.5 introduces top-down protein sequencing using tandem mass spectrometry (MS/MS) to address the growing need to rapidly analyze expected drug proteoforms--for example, in biosimilar assessment--on an industrial scale. This release further enhances the established characterization workflows built into Genedata Expressionist for the identification of multiple clipping events in biotherapeutics. Smart filters reduce the number of false-positive clipping results that are typically obtained in such analyses, significantly reducing the time required to review large data sets. These new capabilities enable scientists working in biopharma to not only meet current and emerging analytical challenges, but also allow them to keep pace with ever-increasing molecular complexity and process scale.
As the industry leader in end-to-end automation of MS data analysis, Genedata Expressionist now offers automated product quality monitoring of emerging modalities--such as therapeutic oligonucleotides. Expert users can easily define critical quality attributes (CQAs) of any molecular structure and monitor them using routine automated processes. The generated results can be verified using a new interactive CQA review process, enabling users to leverage and integrate their knowledge into the overall automated workflow. With the introduction of these novel product quality monitoring capabilities, this release further cements the position of Genedata Expressionist as the platform of choice for the automation of MS data analysis across all stages of drug discovery, development, and manufacturing.
"The inherent complexity of innovative biotherapeutics necessitates comprehensive characterization and robust product quality assessment. The new characterization functionalities in Genedata Expressionist 16.5 deliver deeper insights, enabling our industry partners to ensure the safety and efficacy of their drugs, while novel automation capabilities for CQA monitoring accelerate and streamline processes throughout R&D," stated Othmar Pfannes, Ph.D., CEO of Genedata. "We will continue to work closely with leading biopharma companies to deliver the automated data processing solutions required to develop next-generation therapies."
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com | LinkedIn | Twitter | YouTube
________________________________________
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Media Contact
Allison Kurz, Genedata, +41615118459, pr@genedata.com
SOURCE Genedata
|
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
|
